Spyre Therapeutics Inc(SYRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.18 | Insider Own | 10.22% | Shs Outstand | 88.1M | Perf Week | 6.9% |
| Market Cap | 8.91B | Forward P/E | - | EPS next Y | -28.65% | Insider Trans | -35.32% | Shs Float | 82.9M | Perf Month | 7.37% |
| Enterprise Value | 7.91B | PEG | - | EPS next Q | -0.78 | Inst Own | 108.29% | Short Float | 15.09% | Perf Quarter | 1.72% |
| Income | -0.17B | P/S | - | EPS this Y | -37.45% | Inst Trans | 17.09% | Short Ratio | 10.41 | Perf Half Y | 39.1% |
| Sales | 0.00B | P/B | 8.91 | EPS next 5Y | -27.79% | ROA | -19.65% | Short Interest | 12.51M | Perf YTD | 194.75% |
| Book/sh | 10.84 | P/C | 7.78 | EPS past 3/5Y | 57.01% 44.61% | ROE | -21.61% | 52W High | -12.36% ($110.18) | Perf Year | 298.02% |
| Cash/sh | 12.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -15.28% | 52W Low | 356.66% ($21.15) | Perf 3Y | 726.71% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.51% | Gross Margin | - | Volatility(W/M) | 4.28% 5.62% | Perf 5Y | -47.23% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 4.63 | Perf 10Y | -33.41% |
| Dividend Ex-Date | - | Quick Ratio | 18.53 | EPS Q/Q | 29.38% | Profit Margin | - | RSI (14) | 59.06 | Recom | 1.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.53 | Sales Q/Q | - | SMA20 | 9.53% ($88.16) | Beta | 3.26 | Target Price | $122.33 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/4 | SMA50 | 7.22% ($90.06) | Rel Volume | 0.55 | Prev Close | $98.96 |
| Employees | 102 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 52.56% - | SMA200 | 31.87% ($73.22) | Avg Volume(3M) | 1.20M | Price | $96.56 |
| IPO | 2016/4/7 | Option/Short | Yes/Yes | Trades | 11509 | Volume | 661,067 | Change | -2.43% |
🧬 A clinical-stage biotech company developing antibody-based therapeutics for inflammatory bowel disease (IBD). It targets conditions such as ulcerative colitis and Crohn's disease with next-generation antibody candidates designed to extend dosing intervals and enhance efficacy through combination therapy. As a biotech healthcare stock, its share price is driven by clinical results and funding conditions.
Over the past 1 year, on the higher side
12% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
SYRE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -37.5% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -47.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 108.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #30 of 597 in the industry
Based on market cap of $9B.
TGTX#29 TG Therapeutics Inc $9B PER 22.3 SYRE#30 Spyre Therapeutics Inc $9B PER - 
IBRX#31 ImmunityBio Inc $9B PER - 
CORT#32 Corcept Therapeutics Inc $9B PER 193.7 
CYTK#33 Cytokinetics Inc $9B PER - 
FAQ
What kind of company is SYRE?
SYRE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SYRE?
The market cap of SYRE is approximately $8.9B, ranking 982 within its sector.
What is the 52-week high and low for SYRE?
SYRE has recorded a 52-week high of $110.18 and a low of $21.15.
